Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Comparison of Bupropion SR and Placebo for Smoking Cessation

This study has been completed.
VA Office of Research and Development
Information provided by (Responsible Party):
Robert W. Buchanan, University of Maryland Identifier:
First received: September 13, 2005
Last updated: March 30, 2017
Last verified: March 2017
The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of successful abstinence in this population. If bupropion SR is effective for reducing cigarette smoking, then it will be important to determine if decreased nicotine intake is associated with a worsening of psychotic, anxiety or depressive symptoms. In addition, it would be important to determine the effect that a reduction in nicotine stimulation would have on patient's cognitive functioning, as nicotinic receptors have been shown to regulate attention and memory function, and it is hypothesized that these functions are normalized by acute nicotine administration in people with schizophrenia

Condition Intervention Phase
Tobacco Use Disorder
Drug: Bupropion SR
Drug: Placebo Oral Tablet
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Comparison of Bupropion SR and Placebo for Smoking Cessation

Resource links provided by NLM:

Further study details as provided by University of Maryland:

Primary Outcome Measures:
  • The Fagerstrom Test for Nicotine Dependence, expired CO level, and urine cotinine will be used to determine if bupropion SR, when used as an adjunct to antipsychotic medication, is superior to placebo for helping patients with schizophrenia improve their [ Time Frame: Expired CO weekly, Fagerstrom baseline and end of study, Urine cotinine baseline, week 2 and week 8 ]
  • Neuropsychological testing will be used to determine the effects of smoking cessation on patient's attention and memory function. [ Time Frame: Beginning and end of study ]

Secondary Outcome Measures:
  • BPRS, SANS, EPRS, and body weight will be used to determine the effects of bupropion SR and smoking cessation on patients' positive and negative symptoms, level of functioning, and physical health. [ Time Frame: Baseline, week 2, 4, 8, and 14 ]
  • To determine whether responses to the Smoking Consequences Questionnaire, Change Assessment Scale, Temptation to Smoke Scale, Decisional Balance Scale, and Smoking Abstinence Self-Efficacy Scale correlate with successful smoking cessation. [ Time Frame: Beginning and end of study ]

Enrollment: 52
Study Start Date: April 2001
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Bupropion SR Drug: Bupropion SR
150mg twice a day (starting with 150mg once a day for three days)
Placebo Comparator: Placebo Drug: Placebo Oral Tablet
Comparable placebo

  Show Detailed Description


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Inclusion Criteria are:

    1. DSM-IV diagnosis of Schizophrenia or schizoaffective disorder
    2. Age: 18-64
    3. Regular half pack a day smokers
    4. Score of at least 4 on the Nicotine Dependency Test

      Exclusion Criteria:

      Exclusion Criteria are:

    1. Seizure disorders, other Neurologic illnesses, or a family history of seizures
    2. A medical condition that could manifest psychiatrically
    3. Currently experiencing a depressive episode
    4. Active substance abuse
    5. Currently receiving bupropion
    6. Pregnant women
    7. Children (<18 years of age)
    8. Two consecutive sodium levels of 130 mmol/L or less
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00176449

United States, Maryland
Maryland Psychiatric REsearch Center
Catonsville, Maryland, United States, 21228
Sponsors and Collaborators
University of Maryland
VA Office of Research and Development
Principal Investigator: Elaine E Weiner, MD University of Maryland
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Robert W. Buchanan, Chief, Maryland Psychiatric Research Center, Outpatient Research Program, University of Maryland Identifier: NCT00176449     History of Changes
Other Study ID Numbers: 2407ko
Study First Received: September 13, 2005
Last Updated: March 30, 2017

Keywords provided by University of Maryland:
Nicotine Dependence
Nicotine Use Disorder
Tobacco Dependence
Tobacco-Use Disorder
Smoking Cessation

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on April 28, 2017